On Monday, Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO), lost -0.83% to $8.34.
Inovio Pharmaceuticals, declared it will advance its DNA vaccine for MERS into a phase I clinical trial in healthy volunteers in a partnership with GeneOne Life Science Inc. (011000.KS), an international DNA vaccine developer and manufacturer in which Inovio holds an equity interest. MERS is a respiratory disease caused by a corona-virus, which is related to the severe acute respiratory syndrome virus. Presently, MERS carries a 40% death rate; there is no vaccine or effective treatment for this virus.
Inovio and GeneOne will conduct a phase I trial to evaluate the safety, tolerability and immunogenicity of Inovio’s DNA-based MERS vaccine. The companies are presently conducting pre-IND activities and plan to start the clinical study before year end. GeneOne will conduct and fund the clinical study in return for milestone-based co-ownership of the immunotherapy. Upon successful completion of the study, the companies plan to jointly seek additional third party support and resources to further develop and commercialize this product.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
Shares of NeoPhotonics Corp (NYSE:NPTN), inclined 8.19% to $ 8.98, during its last trading session.
NeoPhotonics Corporation, declared the closing of the underwriters’ formerly exercised over-allotment option to purchase 895,655 additional shares of common stock at $7.25 per share (less the underwriting discount). With this option exercised, the company’s follow-on offering totals 6,866,689 shares of common stock.
NeoPhotonics Corporation designs and manufactures hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks.
At the end of Monday’s trade, Shares of Apollo Education Group Inc (NASDAQ:APOL), gained 2.96% to $ 17.07.
Apollo Education Group, declared it will accept the ACT National Career Readiness Certificate for up to three credits towards elective courses in select University undergraduate degree programs. The initiative is part of the University’s commitment to aligning degree programs with industry standards, and assisting students more quickly and affordably achieve their education aims based on their relevant experience.
Apollo Education Group, Inc. provides private education services. It offers online and on-campus undergraduate, graduate, professional development, and other non-degree educational programs and services primarily to working learners in the United States and internationally.
Finally, TG Therapeutics Inc (NASDAQ:TGTX), ended its last trade with 4.07% gain, and close at $ 16.38.
TG Therapeutics, declared clinical results from its ongoing study with TG-1101 (ublituximab), the Company’s novel glycol-engineered anti-CD20 monoclonal antibody in combination with the Company’s oral, once-daily, PI3K delta inhibitor, TGR-1202 and ibrutinib, a BTK inhibitor. Data from this Phase I dose escalation study was presented recently by Dr. Nathan Fowler, Director, Developmental Therapeutics, Department of Lymphoma, MD Anderson Cancer Center at the Lymphoma Oral Session during the 51st American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
Michael S. Weiss, the Company’s Executive Chairman and Interim CEO commented on the data, “The ability to safely combine these three agents highlights why we have been so focused on the importance of the safety profile of our proprietary combination of TG-1101 plus TGR-1202, which we refer to as “TG-1303″. We firmly believe the future paradigm for the treatment of B-cell malignancies will comprise of the combination of multiple novel non-chemotherapy agents, where the safety profile of the chosen backbone regimen, like TG-1303, will be critical. A favorable safety profile is critical to unlocking the potential to explore whether dramatic activity with these novel multiple drug combinations can be seen. We believe Dr. Fowler presented some intriguing evidence of noteworthy activity across multiple B-cell malignancy sub-types using this novel chemotherapy-free triple combination made possible by the 1303 safety profile.” Mr. Weiss continued, “We look forward to ongoing to explore this and other novel triple combinations in the future as we drive to create best-in-class combinations that can materially and positively impact the lives of those living with B-cell malignancies.”
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for b-cell malignancies and autoimmune diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
